Terumo Corporation · TSE:4543
Terumo — Investor Presentation (May 2015)
9 slides from Terumo's investor presentation, May 8, 2015
Slide 1: Initiatives for Sustainable Growth
Initiatives for Sustainable Growth Terumo Corporation President and Representative Director Yutaro Shintaku May. 8, 2015 1/9
Slide 2: Update on the "Roadmap to FY16"
Update on The “Roadmap to FY16” Secure a foothold in FY13-14 *1OPM Target in FY16 20% ⇒Transformed product portfolio of Hospital and 20.0% Laboratory Business in Europe Actual 17.5% 17.4% Closed the factory for blood bags in 17.3% Changchun, China 17.0% Guidance Achieve FY14 guidance 15% ⇒Achieved
Slide 3: Proactively Addressing Environmental Changes
Proactively Addressing Environmental Changes Respond to environmental changes in corporate governance • Transition to “a Company with an Audit/Supervisory Committee” based on the Act for the Partial Amendment of the Companies Act • Comply with the Corporate Governance Code ⇒Both initiatives aiming
Slide 4: Highlights of Cardiac & Vascular Company
Highlights of Cardiac & Vascular Company Expand business of Interventional Oncology (Cancer treatment) • Double-digit growth expected • Terumo’s unique competitiveness can be leveraged in this field. Expand business based on transcatheter arterial chemoembolization with drug-chargeable embolic part
Slide 5: Launch Ultimaster in Japan and Further Gain Market Share
Launch Ultimaster in Japan and Further Gain Market Share Our DES market share is expected to surpass the record-high 10%. Thousand units •Great system maneuverability and lesion accessibility 300 •Applicable to complex lesions 15% •Broader size variation 200 10% Ultimaster (sales units) Nobori (sale
Slide 6: Neurovascular: Continue to Expand Sales of Non-coil New Products
Neurovascular：Continue to Expand Sales of Non-coil New Products Billion yen <% share of sales> Clot retriever Flow Non-coil diverter 49% Occlusion balloon 20% Coil Coil 51% 80% © Terumo Corporation 2015/5/8 6/9
Slide 7: Highlights of General Hospital Company
Highlights of General Hospital Company Improve profitability of I.V. solutions through production technology innovation Self-monitoring blood glucose meter: Aim for top market share in Japan Innovation history of “Needle and Syringe” • Prefilled syringes (1999-): Improved safety • Nanopass (2005-
Slide 8: Highlights of Blood Management Company
Highlights of Blood Management Company ■Improve operational efficiency and reduce manufacturing costs to deal with price erosion • The new factory, Terumo BCT Vietnam, is scheduled to begin its operation in Q3 FY2015 ■Accelerate growth of high-margin products (CAGR for last 3 years: 10%) • Therapeut
Slide 9: IR Contact
IR Contact Terumo Corporation Corporate Communication (IR) Dept. E-mail: [email protected] Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not i